Hemodynamic changes caused by glibenclamide in isolated, working, erythrocyte perfused rat heart.
Glibenclamide-induced cardiac hemodynamic changes before and after ischemia have been frequently studied. In general a Langendorff buffer perfused heart model was used to examine these effects. However these models used protein-free buffer perfusates. To improve clinical relevance and thereby enhance extrapolation to the in vivo condition we studied the effects of glibenclamide on cardiac hemodynamics using a working, erythrocyte perfused, rat heart model, where the perfusate was enriched with albumin. The results show a dose-dependent decline in CBF in normoxia and at the end of reperfusion (after an ischemic period) with glibenclamide treatment compared to control. Cardiac functional recovery improved with 1 and 4 mumol.L-1 glibenclamide concentrations. From this study it seems that there is a marked decrease in CBF but this did not result in impaired myocardial function after a period of ischemia, so it appears that there are no startling side effects of glibenclamide in the ischemic rat heart.
Legtenberg
R J
RJ
Department of Physiology 237, Faculty of Medical Sciences, University of Nijmegen, The Netherlands.
Houston
R J
RJ
Smits
P
P
Oeseburg
B
B
D000818:Animals; D003331:Coronary Vessels / Q000187:drug effects* / Q000503:physiopathology; D004912:Erythrocytes; D005905:Glyburide / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D026902:Potassium Channel Blockers; D051381:Rats; D017208:Rats, Wistar
D007004:Hypoglycemic Agents; D026902:Potassium Channel Blockers; D005905:Glyburide